头盔无创通气与常规呼吸支持治疗COVID-19患者的长期结局:Helmet-COVID随机临床试验随访研究
本研究为Helmet-COVID随机临床试验的预设随访研究,多中心纳入320例COVID-19所致急性低氧性呼吸衰竭成人患者,随机接受头盔无创通气或常规呼吸支持。改良意向治疗人群排除3例失访,主要结局为180天死亡率、EQ-5D-5L指数值和EQ-VAS评分。180天内头盔无创通气组63/159例(39.6%)死亡,常规呼吸支持组65/158例(41.1%)死亡,风险差-1.5%(95%CI -12.3, 9.3,p=0.78)。两组EQ-5D-5L指数值(中位0.68 vs 0.67,中位差0.00,95%CI -0.32, 0.32,p=0.91)和EQ-VAS评分(中位70 vs 70,中位差0.00,95%CI -31.92, 31.92,p=0.55)均无差异。结论认为头盔无创通气未降低180天死亡率或改善健康相关生活质量。
要点
- 在COVID-19肺炎所致急性低氧性呼吸衰竭成人中,头盔无创通气组180天死亡63/159例(39.6%),常规呼吸支持组65/158例(41.1%),风险差-1.5%(95%CI -12.3, 9.3,p=0.78)。
- 改良意向治疗分析中,头盔无创通气组与常规呼吸支持组EQ-5D-5L指数值无差异(中位0.68 vs 0.67,中位差0.00,95%CI -0.32, 0.32,p=0.91)。
- 两组EQ-VAS评分无差异(中位70 vs 70,中位差0.00,95%CI -31.92, 31.92,p=0.55)。
- 该随访研究结论:头盔无创通气未降低180天死亡率或改善健康相关生活质量。
适用人群与场景
- COVID-19肺炎所致急性低氧性呼吸衰竭成人患者,多中心随机临床试验纳入n=320。
研究设计与关键结果
- 研究类型:Helmet-COVID随机临床试验的预设随访研究,多中心设计。
- 纳入320例COVID-19所致急性低氧性呼吸衰竭成人,随机接受头盔无创通气或常规呼吸支持;改良意向治疗人群排除3例失访。
- 主要结局180天死亡率:头盔无创通气组63/159例(39.6%)vs 常规呼吸支持组65/158例(41.1%),风险差-1.5%(95%CI -12.3, 9.3,p=0.78)。
- EQ-5D-5L指数值:头盔无创通气组中位0.68(IQR 0.00, 1.00)vs 常规呼吸支持组中位0.67(IQR 0.00, 1.00),中位差0.00(95%CI -0.32, 0.32,p=0.91)。
- EQ-VAS评分:头盔无创通气组中位70(IQR 0, 93)vs 常规呼吸支持组中位70(IQR 0, 90),中位差0.00(95%CI -31.92, 31.92,p=0.55)。
- 改良意向治疗分析中,死亡者EQ-5D-5L和EQ-VAS赋值为0。
证据类型、等级与局限
- 证据类型:随机临床试验(Helmet-COVID)的预设随访研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在COVID-19肺炎所致急性低氧性呼吸衰竭患者中,头盔无创通气与常规呼吸支持相比未降低180天死亡率,也未改善健康相关生活质量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate whether helmet noninvasive ventilation compared to usual respiratory support reduces 180-day mortality and improves health-related quality of life (HRQoL) in patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia.
METHODS: This is a pre-planned follow-up study of the Helmet-COVID trial. In this multicenter, randomized clinical trial, adults with acute hypoxemic respiratory failure (n = 320) due to coronavirus disease 2019 (COVID-19) were randomized to receive helmet noninvasive ventilation or usual respiratory support. The modified intention-to-treat population consisted of all enrolled patients except three who were lost at follow-up. The study outcomes were 180-day mortality, EuroQoL (EQ)-5D-5L index values, and EQ-visual analog scale (EQ-VAS). In the modified intention-to-treat analysis, non-survivors were assigned a value of 0 for EQ-5D-5L and EQ-VAS.
RESULTS: Within 180 days, 63/159 patients (39.6%) died in the helmet noninvasive ventilation group compared to 65/158 patients (41.1%) in the usual respiratory support group (risk difference - 1.5% (95% confidence interval [CI] - 12.3, 9.3, p = 0.78). In the modified intention-to-treat analysis, patients in the helmet noninvasive ventilation and the usual respiratory support groups did not differ in EQ-5D-5L index values (median 0.68 [IQR 0.00, 1.00], compared to 0.67 [IQR 0.00, 1.00], median difference 0.00 [95% CI - 0.32, 0.32; p = 0.91]) or EQ-VAS scores (median 70 [IQR 0, 93], compared to 70 [IQR 0, 90], median difference 0.00 (95% CI - 31.92, 31.92; p = 0.55).
CONCLUSIONS: Helmet noninvasive ventilation did not reduce 180-day mortality or improve HRQoL compared to usual respiratory support among patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia.
参考来源
- Arabi YM, Al-Dorzi HM, Aldekhyl S, et al. Long-term outcomes of patients with COVID-19 treated with helmet noninvasive ventilation or usual respiratory support: follow-up study of the Helmet-COVID randomized clinical trial. Intensive Care Med. 2023. PMID: 36820878. doi:10.1007/s00134-023-06981-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。